A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Abstract Background Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma subtype which remains incurable despite multimodal approach including chemoimmunotherapy followed by stem cell transplant, targeted approaches such as the BTK inhibitor ibrutinib, and CD19 chimeric antigen receptor...

Full description

Bibliographic Details
Main Authors: Wing Keung Chan, Jessica Williams, Kinnari Sorathia, Betsy Pray, Kaled Abusaleh, Zehua Bian, Archisha Sharma, Ian Hout, Shamama Nishat, Walter Hanel, Shelby L. Sloan, Aneeq Yasin, Nathan Denlinger, Xiaoli Zhang, Natarajan Muthusamy, Sumithira Vasu, Marcos de Lima, Yiping Yang, Robert Baiocchi, Lapo Alinari
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Experimental Hematology & Oncology
Subjects:
Mantle cell lymphoma
CD74
Chimeric antigen receptor
Online Access:https://doi.org/10.1186/s40164-023-00437-8

Internet

https://doi.org/10.1186/s40164-023-00437-8

Similar Items